### Antibiotic (brand name) | Concentration | Stability at 4°C | Reference
--- | --- | --- | ---
Ampicillin | 30 mg/mL ≤20 mg/mL | W: 48h; NS: 24h | Pt: Pfizer; New York NY, 2010.
Ampicillin/sulbactam (Unasyn®) | 30/15 mg/mL 20/10 mg/mL | W, NS: 48h W, NS: 72h; D5W: 4h | Pt: Pfizer; New York NY, 2014.
Aztreonam (Azactam®) | 100 mg/mL | W, NS: 7d | Pt: Bristol-Myers Squibb; Princeton NJ, 2013
Cefotaxime (Claforan®) | 100 mg/mL | W, NS, D5W: 5d | Pt: Sanofi-Aventis; Bridgewater NJ, 2007.
Ceftazidime (Fortaz®, Tazicef®) | 60 mg/mL 100 mg/mL | NS: 10d1 W, NS, D5W: 7d,2,3 | 1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24. 2. PT GlaxoSmithKline; Research Triangle Park NC, 2004. 3. PT Hospira Worldwide; Lake Forest IL, 2014.
Ceftriaxone (Rocephin®) | 40 mg/mL 100 mg/mL | NS: 23d; D5W: 26d1 W, NS D5W: 10d2 | 1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24. 2. PT Genentech USA; South San Francisco CA, 2015.
Imipenem/cilastin (Primaxin*) | 5 mg/mL | NS, D5W: 24h | Pt: Merck; Whitehouse Station NJ, 2014.
Oxacillin (Oxacillin®)c | 200 mg/mL (W, D5W) 100 mg/mL (NS) | W: Not recommended at 4°C; 84h at RT NS: ≥2wk D5W: Not recommended at 4°C; 42h at RT | Fugit KD, Anderson BD. Antibiotic Stability in Freedom60 Syringe Report By HealthTek™ and the University of Kentucky, Lexington. Chester, NY: RMS; 2015.
Penicillin G (Pfizerpen®) | 50,000 U/mL | W, NS, D5W: 7d | Pt: Pfizer; New York NY, 2005.
Piperacillin/tazobactam (Zosyn®) | 0.1125 g/mL | W, NS, D5W: 7d | Pt: Pfizer, Wyeth; Philadelphia PA, 2012.
Cl: Cefazolin (Ancef®) | 40 mg/mL 100 to 200 mg/mL | NS: 10d; 1.5d at RT W, NS, D5W: 7d at 4°C; 24h1 at RT2,3 | 1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24. 2. PT GlaxoSmithKline; Research Triangle Park NC, 2004. 3. PT Hospira Worldwide; Lake Forest IL, 2014.
Cl: Cefotaxime (Claforan®) | 100 mg/mL | W, NS, D5W: 5d | Pt: Sanofi-Aventis; Bridgewater NJ, 2007.
Cl: Cefazidime (Fortaz®, Tazicef®) | 60 mg/mL 100 mg/mL | NS: 10d; 1.5d at RT W, NS, D5W: 7d at 4°C; 24h1 at RT2,3 | 1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24. 2. PT GlaxoSmithKline; Research Triangle Park NC, 2004. 3. PT Hospira Worldwide; Lake Forest IL, 2014.
Cl: Meropenem (Merrem*) | 50 mg/mL | W: 44h NS: 40h D5W: 25h W, NS: 8h at RT D5W: 5h at RT | Fugit KD, Anderson BD. Antibiotic Stability in Freedom60 Syringe Report By HealthTek™ and the University of Kentucky, Lexington. Chester, NY: RMS; 2015.
Cl: Piperacillin/tazobactam (Zosyn®) | 0.1125 g/mL | W, NS, D5W: 7d | Pt: Pfizer, Wyeth; Philadelphia PA, 2012.

Cl = continuous infusion; D5W = 5% dextrose in water; NS = normal saline (0.9%); RT = room temperature; W = sterile water for injection.

**Special Notes:** *Refrigerated or frozen, clindamycin forms crystals which must be resolubilized before administration. Clindamycin is incompatible with natural rubber closures because it may extract to form crystal particulates, so RT storage in disposable syringes should be limited to a few days; *Ertapenem should not be reconstituted or mixed with solutions containing dextrose; *Oxacillin sodium can be extremely irritating to veins at higher concentrations; *Administer higher concentrations via a central line to avoid irritation; *durations >90 min may be required if Redman syndrome develops.*